Business
Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting
LEXINGTON, Mass., February 24, 2025--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented data at the American Association for Cancer Research (AACR) IO Annual Meeting in Los Angeles, California. The oral presentation highlights translational data from the ongoing Phase 2 study evaluating botensilimab (BOT, multifunctional Fc-enhanced anti-CTLA-4) and balstilimab (BAL, anti-PD-1) in combination with MiNK Therapeutics’ agenT-797, an allogeneic invariant natural killer T (iNKT)
About this update from Agenus Inc.
[{"type":"text","content":"Combination of Botensilimab/Balstilimab with MiNK Therapeutics’ AgenT-797 Shows Strong Immune Activation and Potential to Enhance Outcomes in Refractory Gastric Cancer","length":167,"tagName":"p","attribs":{}},{"type":"text","content":"LEXINGTON, Mass., February 24, 2025--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented data at the American Association for Cancer Research (AACR) IO Annual Meeting in Los Angeles, California. The oral presentation highlights translational data from the ongoing Phase 2 study evaluating botensilimab (BOT, multifunctional Fc-enhanced anti-CTLA-4) and balstilimab (BAL, anti-PD-1) in combination with MiNK Therapeutics’ agenT-797, an allogeneic invariant natural killer T (iNKT) cell therapy, in patients with refractory (2L+) gastric cancer (NCT06251973).","length":595,"tagName":"p"},{"type":"text","content":""These latest data demonstrate the remarkable potential of combining BOT/BAL with a novel iNKT cell therapy to broaden and intensify immune responses against resistant gastric tumors," said Dr. Dhan Chand, Vice President of Research at Agenus. "By driving strong IFNγ production, deep T-cell infiltration, and memory T-cell activation—even in PD-1–refractory patients—the addition of agenT-797 to BOT/BAL could redefine what’s possible in late-line gastric cancer. We’re particularly encouraged by how these therapies work in concert with standard-of-care chemotherapy to transform immunologically 'cold' tumors into 'hot' immune inflamed tumors, potentially offering a new therapeutic paradigm for patients facing this challenging disease."","length":777,"tagName":"p"},{"type":"text","content":"Highlights","length":10,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Broad Immune Activation: The addition of MiNK’s allogeneic iNKT therapy, agenT-797, to BOT/BAL drove robust immune activation, including elevated interferon-gamma (IFNγ) levels, indicating potent systemic engagement and overcoming immunosuppressive pathways in PD-1–refractory gastric tumors.","length":292,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Enhanced T cell Infiltration and Memory T-Cell Expansion: A marked increase in tumor-infiltrating lymphocytes (TILs), together with heightened peripheral memory T-cell activation, un...